Revolution Medicines, Inc. shares surged on strong Phase 1 data for daraxonrasib in metastatic pancreatic cancer. Click here to read why RVMD stock is a Buy.
Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George ...
Long-term follow-up data for daraxonrasib monotherapy in second line metastatic pancreatic ductal adenocarcinoma reinforces ...
"The findings being presented at AFS underscore the importance of moving beyond standard pathology when assessing progression ...
News-Medical.Net on MSN
Why universal COVID-19 vaccine guidance offers stronger protection than high-risk-only policies
The US Scenario Modeling Hub’s nine-team ensemble projected COVID-19 hospitalizations and deaths for April 2024 to April 2025 ...
The Real Estate Debt Fund launched March 31, 2025. Institutional shares returned 2.02% during the second quarter, and the ...
FLAURA2 phase III trial of AstraZeneca’s Tagrisso plus chemotherapy demonstrated a median overall survival in EGFR-mutated advanced lung cancer: Cambridge, UK Tuesday, September ...
Starbucks CEO Brian Niccol made $95.8 million in 2024, while the median barista at the company made just $14,674, according to the AFL-CIO. The CEO-to-worker pay ratio of 6,666-to-1 is the largest ...
Li-Fraumeni syndrome (LFS) is a high-risk hereditary cancer predisposition syndrome affecting 1 in 5000 individuals. Current ...
Up to a quarter of patients with classical Hodgkin’s lymphoma (HL) are resistant or have disease relapse after first-line ...
Utilizing market research to inform decision-making begins with clearly identifying the objective: What specific goal am I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback